Top 10 Developments in Lupus Nephritis

被引：5
|
作者：
Chen, Teresa K. [1 ]
Fine, Derek M. [1 ]
机构：
[1] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD 21205 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2013年 / 15卷 / 09期
关键词：
Lupus nephritis; Kidney; Proliferative lupus nephritis; Membranous lupus nephritis; Renal transplantation; APOL1; Induction therapy; Maintenance therapy; Systemic lupus erythematosus; SLE; Mycophenolatemofetil; Rituximab; Treatment; Multitargeted therapy; Epidemiology; B-LYMPHOCYTE STIMULATOR; STAGE RENAL-DISEASE; MYCOPHENOLATE-MOFETIL; CONTROLLED-TRIAL; DOUBLE-BLIND; COLLAPSING GLOMERULOPATHY; MEMBRANOUS NEPHROPATHY; CLINICAL-TRIALS; ERYTHEMATOSUS; THERAPY;
D O I：
10.1007/s11926-013-0358-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Lupus nephritis affects up to 60 % of patients with systemic lupus erythematosus and is associated with worse clinical outcomes. Traditionally, it has been treated with high-dose immunosuppression consisting of cyclophosphamide and prednisone; however, recent trials have demonstrated mycophenolate mofetil as a safe and effective alternative for both induction and maintenance of disease. Other progress has been made in our understanding of the pathogenesis of lupus nephritis, outcomes in renal transplantation, and associations with genetic risk factors. This review highlights key developments in our understanding of lupus nephritis over the past decade.
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Lupus nephritis: Up-to-date
    Karras, A.
    REVUE DE MEDECINE INTERNE, 2015, 36 (02): : 98 - 106
  • [22] Cellular aspects of the pathogenesis of lupus nephritis
    Chang, Anthony
    Clark, Marcus R.
    Ko, Kichul
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (02) : 197 - 204
  • [23] Renal Involvement in Connective Tissue Diseases - part 1: Lupus Nephritis
    Oelzner, Peter
    Amann, Kerstin
    Wolf, Gunter
    AKTUELLE RHEUMATOLOGIE, 2020, 45 (02) : 150 - 162
  • [24] Can we manage lupus nephritis without chronic corticosteroids administration?
    Lightstone, Liz
    Doria, Andrea
    Wilson, Hannah
    Ward, Frank L.
    Larosa, Maddalena
    Bargman, Joanne M.
    AUTOIMMUNITY REVIEWS, 2018, 17 (01) : 4 - 10
  • [25] Clinical approach to lupus nephritis: Recent advances
    Molino, C.
    Fabbian, F.
    Longhini, C.
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2009, 20 (05) : 447 - 453
  • [26] Clinical efficacy and safety of rituximab in lupus nephritis
    Zhong, Zhiqing
    Li, Hongyan
    Zhong, Hongzhen
    Zhou, Tianbiao
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 845 - 856
  • [27] Diagnostic and therapy of lupus nephritis-2023
    Odler, Balazs
    Pollheimer, Marion J.
    Kronbichler, Andreas
    Saeemann, Marcus D.
    Windpessl, Martin
    Gauckler, Philipp
    Rudnicki, Michael
    Zitt, Emanuel
    Neumann, Irmgard
    Lhotta, Karl
    Eller, Kathrin
    WIENER KLINISCHE WOCHENSCHRIFT, 2023, 135 (SUPPL 5) : 675 - 687
  • [28] Management of refractory lupus nephritis: challenges and solutions
    Yo, J. H.
    Barbour, T. D.
    Nicholls, K.
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2019, 11 : 179 - 188
  • [29] Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis
    van Tellingen, A.
    Voskuyl, A. E.
    Vervloet, M. G.
    Bijl, M.
    de Sevaux, R. G. L.
    Berger, S. P.
    Derksen, R. H. W. M.
    Berden, J. H. M.
    NETHERLANDS JOURNAL OF MEDICINE, 2012, 70 (04) : 199 - 206
  • [30] Cyclophosphamide and Lupus Nephritis: When, How, For How Long?
    Ntali, Stella
    Bertsias, George
    Boumpas, Dimitrios T.
    CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY, 2011, 40 (03) : 181 - 191
12345